Vistagen CEO acquires 36,818 shares via ESPP
Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired shares of the company through an employee stock purchase program.
Rhea-AI Filing Summary
Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired shares of the company through an employee stock purchase program. He received 36,818 shares of common stock at a purchase price of $0.1921 per share under Vistagen's 2019 Employee Stock Purchase Plan, as amended. This plan-related acquisition is classified as a grant or award and is exempt under Rule 16b-3.
Following this acquisition, Singh directly holds 54,846 shares of Vistagen common stock. The filing also reports an additional 20,875 shares of common stock held indirectly by The 1997 Singh Family Trust U/R/D 05/29/1997, reflecting family trust ownership separate from his direct holdings.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 36,818 | $0.1921 | $7K |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP.
- F2. Shares held by The 1997 Singh Family Trust U/R/D 05/29/1997.
Key Figures
Key Terms
Employee Stock Purchase Plan financial
ESPP financial
Rule 16b-3 regulatory
indirect ownership financial
FAQ
What insider transaction did Vistagen (VTGN) CEO Shawn Singh report?
What is The 1997 Singh Family Trust’s position in Vistagen (VTGN)?
Did Shawn Singh purchase the maximum amount allowed under Vistagen’s ESPP?
AI-generated analysis. How Rhea-AI works. Not financial advice.